These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 24697955)

  • 1. Pharmacokinetics of mycophenolate mofetil in children with lupus and clinical findings in favour of therapeutic drug monitoring.
    Woillard JB; Bader-Meunier B; Salomon R; Ranchin B; Decramer S; Fischbach M; Berard E; Guigonis V; Harambat J; Dunand O; Tenenbaum J; Marquet P; Saint-Marcoux F
    Br J Clin Pharmacol; 2014 Oct; 78(4):867-76. PubMed ID: 24697955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic study of mycophenolate mofetil in patients with systemic lupus erythematosus and design of Bayesian estimator using limited sampling strategies.
    Zahr N; Amoura Z; Debord J; Hulot JS; Saint-Marcoux F; Marquet P; Piette JC; Lechat P
    Clin Pharmacokinet; 2008; 47(4):277-84. PubMed ID: 18336056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a Bayesian estimator for the therapeutic drug monitoring of mycophenolate mofetil in children with idiopathic nephrotic syndrome.
    Saint-Marcoux F; Guigonis V; Decramer S; Gandia P; Ranchin B; Parant F; Bessenay L; Libert F; Harambat J; Bouchet S; Broux F; Compagnon P; Marquet P
    Pharmacol Res; 2011 May; 63(5):423-31. PubMed ID: 21272643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Limited sampling strategy and population pharmacokinetic model of mycophenolic acid in pediatric patients with systemic lupus erythematosus: application of a double gamma absorption model with SAEM algorithm.
    Koloskoff K; Benito S; Chambon L; Dayan F; Marquet P; Jacqz-Aigrain E; Woillard JB
    Eur J Clin Pharmacol; 2024 Jan; 80(1):83-92. PubMed ID: 37897528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of mycophenolic acid and external evaluation of two limited sampling strategies of drug exposure in patients with juvenile systematic lupus erythematosus.
    Beaulieu Q; Zhang D; Melki I; Baudouin V; Goldwirst L; Woillard JB; Jacqz-Aigrain E
    Eur J Clin Pharmacol; 2022 Jun; 78(6):1003-1010. PubMed ID: 35294622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus.
    Musuamba FT; Rousseau A; Bosmans JL; Senessael JJ; Cumps J; Marquet P; Wallemacq P; Verbeeck RK
    Clin Pharmacokinet; 2009; 48(11):745-58. PubMed ID: 19817503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mycophenolic acid area under the curve correlates with disease activity in lupus patients treated with mycophenolate mofetil.
    Zahr N; Arnaud L; Marquet P; Haroche J; Costedoat-Chalumeau N; Hulot JS; Funck-Brentano C; Piette JC; Amoura Z
    Arthritis Rheum; 2010 Jul; 62(7):2047-54. PubMed ID: 20506558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and pharmacodynamics of mycophenolic acid and their relation to response to therapy of childhood-onset systemic lupus erythematosus.
    Sagcal-Gironella AC; Fukuda T; Wiers K; Cox S; Nelson S; Dina B; Sherwin CM; Klein-Gitelman MS; Vinks AA; Brunner HI
    Semin Arthritis Rheum; 2011 Feb; 40(4):307-13. PubMed ID: 20655577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic drug monitoring of mycophenolate mofetil and enteric-coated mycophenolate sodium in patients with systemic lupus erythematosus.
    Djabarouti S; Duffau P; Lazaro E; Chapouly C; Greib C; Viallard JF; Pellegrin JL; Saux MC; Breilh D
    Expert Opin Pharmacother; 2010 Apr; 11(5):689-99. PubMed ID: 20210680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bayesian estimation of mycophenolate mofetil in lung transplantation, using a population pharmacokinetic model developed in kidney and lung transplant recipients.
    de Winter BC; Monchaud C; Prémaud A; Pison C; Kessler R; Reynaud-Gaubert M; Dromer C; Stern M; Guillemain R; Knoop C; Estenne M; Marquet P; Rousseau A
    Clin Pharmacokinet; 2012 Jan; 51(1):29-39. PubMed ID: 22054177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mycophenolate mofetil in patients with systemic lupus erythematosus: a prospective pharmacokinetic study.
    Roland M; Barbet C; Paintaud G; Magdelaine-Beuzelin C; Diot E; Halimi JM; Lebranchu Y; Nivet H; Büchler M
    Lupus; 2009 Apr; 18(5):441-7. PubMed ID: 19318398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exposure levels of mycophenolic acid are associated with comorbidities in children with systemic lupus erythematosus.
    Ye Q; Wang G; Lu J; Huang Y; Zhang J; Zhu L; Zhu Y; Lan J; Li Z; Liu Y; Xu H; Li Z
    Lupus; 2021 Oct; 30(11):1808-1818. PubMed ID: 34304630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic modelling and development of Bayesian estimators for therapeutic drug monitoring of mycophenolate mofetil in reduced-intensity haematopoietic stem cell transplantation.
    Saint-Marcoux F; Royer B; Debord J; Larosa F; Legrand F; Deconinck E; Kantelip JP; Marquet P
    Clin Pharmacokinet; 2009; 48(10):667-75. PubMed ID: 19743888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics and Bayesian estimator of mycophenolic acid in children with idiopathic nephrotic syndrome.
    Zhao W; Elie V; Baudouin V; Bensman A; André JL; Brochard K; Broux F; Cailliez M; Loirat C; Jacqz-Aigrain E
    Br J Clin Pharmacol; 2010 Apr; 69(4):358-66. PubMed ID: 20406220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Steady-state mycophenolate mofetil pharmacokinetic parameters enable prediction of systemic lupus erythematosus clinical flares: an observational cohort study.
    Djabarouti S; Breilh D; Duffau P; Lazaro E; Greib C; Caubet O; Saux MC; Pellegrin JL; Viallard JF
    Arthritis Res Ther; 2010; 12(6):R217. PubMed ID: 21176194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limited sampling model for advanced mycophenolic acid therapeutic drug monitoring after liver transplantation.
    Langers P; Press RR; Inderson A; Cremers SC; den Hartigh J; Baranski AG; van Hoek B
    Ther Drug Monit; 2014 Apr; 36(2):141-7. PubMed ID: 24081208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mycophenolic mofetil optimized pharmacokinetic modelling, and exposure-effect associations in adult heart transplant recipients.
    Woillard JB; Saint-Marcoux F; Monchaud C; Youdarène R; Pouche L; Marquet P
    Pharmacol Res; 2015 Sep; 99():308-15. PubMed ID: 26192348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring of mycophenolate mofetil metabolites in children with nephrotic syndrome and the proposed novel target values of pharmacokinetic parameters.
    Sobiak J; Resztak M; Ostalska-Nowicka D; Zachwieja J; Gąsiorowska K; Piechanowska W; Chrzanowska M
    Eur J Pharm Sci; 2015 Sep; 77():189-96. PubMed ID: 26102431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of an abbreviated pharmacokinetic profile for the estimation of mycophenolic acid exposure in pediatric renal transplant recipients.
    Weber LT; Hoecker B; Armstrong VW; Oellerich M; Tönshoff B
    Ther Drug Monit; 2006 Oct; 28(5):623-31. PubMed ID: 17038876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.